Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 1 for:    NCT02406677
Previous Study | Return to List | Next Study

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study (ARTEMIS)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Duke Clinical Research Institute
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT02406677
First received: March 30, 2015
Last updated: April 12, 2017
Last verified: April 2017
  Purpose
Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes. The ARTEMIS trial is a practical multicenter, cluster- randomized clinical trial that will assess the impact of copayment reduction by equalizing the copayment of clopidogrel and ticagrelor. ARTEMIS will assess prescribing patterns, patient medication adherence, and clinical outcomes up to one year. We hypothesize that reducing out--of--pocket cost for P2Y12 receptor inhibitor will lead to improved adherence. Additionally, copayment reduction of both generic and brand antiplatelet agents may lead to a reduction in MACE risk. This is in part due to greater adherence to an evidence--based secondary prevention medication. Additionally the reduction in MACE may reflect greater selection of a more potent antiplatelet agent that has been shown to reduce MACE in randomized clinical trials, as provider choice of antiplatelet therapy will be primarily driven by risk- benefit assessment rather than the cost burden to the patient.

Condition Intervention Phase
Cost Sharing, Acute Coronary Syndrome
Other: Study voucher card
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Health Services Research
Official Title: Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Major Adverse Cardiovascular Events [ Time Frame: 12 months ]
    To determine if patient copayment reduction leads to lower risk of MACE (composite of death, MI, and stroke) at 1 year after discharge.

  • Long Term Persistence to P2Y12 receptor inhibitor [ Time Frame: 12 months ]
    To determine if patient copayment reduction leads to higher long-term persistence of any P2Y12 receptor inhibitor at 1 year after discharge.


Secondary Outcome Measures:
  • P2Y12 receptor inhibitor selection [ Time Frame: 12 months ]
    To evaluate whether reducing patient copayments for both generic and brand P2Y12 receptor inhibitor options affects medication selection at discharge.

  • Healthcare Resource Utilization [ Time Frame: 12 months ]
    To assess the impact of copayment reduction on the total cost of health care for patients after myocardial infarction.


Enrollment: 10848
Actual Study Start Date: June 5, 2015
Estimated Study Completion Date: November 1, 2017
Estimated Primary Completion Date: November 1, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Copayment Intervention Arm
Sites in the intervention arm will provide patients with a study voucher card to offset any patient copayments or medication card for the filling of any prescriptions of clopidogrel or ticagrelor.
Other: Study voucher card
Study voucher card to offset any patient copayments or medication costs for the filling of any prescriptions of clopidogrel or ticagrelor
No Intervention: Usual Care Arm
For hospitals randomized to the control arm, all patients receive usual care and no study intervention is performed.

Detailed Description:
ARTEMIS is a prospective, cluster-randomized clinical trial that will evaluate whether patient copayment elimination significantly influences antiplatelet therapy selection and long-term adherence, as well as patient outcomes and overall cost of care after acute myocardial infarction. Approximately 11,000 patients with ST-elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) will be enrolled at the approximately 300 hospitals in this study. Study sites selected for ARTEMIS will be geographically diverse, and will represent a diversity of hospital types and capabilities (e.g., teaching hospital, community hospital, etc). After institutional review board (IRB) approval of the study, each hospital will be randomized into either the intervention arm or the control arm. Hospitals randomized to the intervention arm will have the opportunity to offer enrolled patients either clopidogrel (generic P2Y12 receptor inhibitor option) or ticagrelor (brand P2Y12 receptor inhibitor option) without patient contribution to copayment in the next 12 months after the index MI discharge. Hospitals in the control arm will provide care per usual clinical routine. Notably, for both intervention and control arms, all patient management decisions (including the choice of antiplatelet therapy) are completely at the discretion of the care providers. Duration of antiplatelet therapy will also be at the discretion of care providers. All enrolled patients will be followed up to 15 months after index MI discharge to collect data on longitudinal treatment patterns and outcomes. Primary and secondary endpoints will be assessed at 12 months. An additional three months of follow up will assess for antiplatelet persistence and clinical events after discontinuation of the copayment intervention. Centralized follow-up will be conducted every 3 months via telephone or web-based contact.
  Eligibility

Ages Eligible for Study:   18 Years to 130 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients are eligible to be included in the study if they meet all of the following criteria:

  • are ≥ 18 years of age
  • have been diagnosed with STEMI or NSTEMI during the index hospitalization
  • be treated with a P2Y12 receptor inhibitor at the time of enrollment
  • have U.S. based health insurance coverage with prescription drug benefit
  • have been fully informed and are able to provide written consent for longitudinal follow-up

Exclusion Criteria:

Patients are excluded if they meet any of the following criteria:

  • have a history of prior intracranial hemorrhage
  • have any contraindications to P2Y12 receptor inhibitor therapy at discharge
  • involvement in another research study that specifies the type and duration of P2Y12 receptor inhibitor use within the next 12 months.
  • have a life expectancy of less than one year
  • have plans to move outside the US in the next year
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02406677

  Show 224 Study Locations
Sponsors and Collaborators
AstraZeneca
Duke Clinical Research Institute
Investigators
Principal Investigator: Tracy Wang, MD, MHS, MSc Duke University
Study Chair: Eric Peterson, MD, MPH, FAHA, FACC Duke University
  More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02406677     History of Changes
Other Study ID Numbers: D5130R00030
Study First Received: March 30, 2015
Last Updated: April 12, 2017

Keywords provided by AstraZeneca:
Acute Coronary Syndromes, ACS, Myocardial Infarction, STEMI, NSTEMI, MI, Co-Payments, Copay, Cost Sharing

Additional relevant MeSH terms:
Infarction
Myocardial Infarction
Acute Coronary Syndrome
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on May 24, 2017